% | $
Quotes you view appear here for quick access.

Amgen Inc. Message Board

rob_cos 11468 posts  |  Last Activity: Jul 8, 2016 2:00 AM Member since: Dec 31, 1997
  • JMP - should CELG experience weakness on JUNO news-consider it a good entry point. We remain bullish on Celgene and we forecast total revenues to rise to $21B+ by 2020. Out top pick. $152 TP

    Celgene Corporation

    Juno Reports Clinical Hold on JCAR015 Phase II ROCKET Trial

    CELG: $104.41 | Market Cap: $81,617M
    Market Outperform | Price Target: $152.00

    Celgene partner Juno Therapeutics (JUNO, NC) announced that it has received notice from the FDA of a clinical hold on its Phase II trial of JCAR015 in adult patients with r/r ALL, known as the “ROCKET” trial; we reiterate our Market Outperform rating and $152 price target based on our discounted cash flow and sum-of-the-parts analyses. The clinical hold was placed after two patient deaths last week, following the recent addition of fludarabine to the pre-conditioning regimen. JUNO's management believes that the combination of fludarabine and JCAR015 induced neurotoxicity that led to fatal cerebral edema in these patients. The company reported that the clinical hold will likely delay the timelines set forth for approval of JCAR015. However, JUNO’s trials and plans for its other CD19-directed CAR-T cell programs, including JCAR017 and JCAR014, are unaffected. We remind investors that CELG retains the rights for JUNO’s CD19 program in Europe and other markets outside of North America and China. Although the clinical hold and resultant delays in the development of JCAR015 represent an obvious detriment to the program, we maintain our $152 price target on CELG as we currently assign no value to this program in our model. Should CELG shares experience weakness in reaction to this news, we would consider it a good entry point for long-term oriented investors. CELG is one of the least expensive of the megacap, profitable biotech names on a PEG basis on FY16 and FY17 numbers.

    We remain bullish on Celgene and we forecast total revenues to rise to $21B+ by 2020. We expect Celgene’s four blockbuster drugs (Revlimid, Abraxane, Otezla, and Pomalyst) to drive revenues approaching $13B by 2017, and over $17B by 2020. Further, we believe the recent acquisition of Receptos and investments in collaborators, such as Acceleron (XLRN, MO, $39 PT), Epizyme (EPZM, MO, $28 PT), OncoMed (OMED, MO, $18 PT), Agios (AGIO, NC), and others, likely ensure growth from 2017 and beyond. We continue to view CELG as our top large-cap pick and reaffirm our Market Outperform rating.

    FIGURE 1. Upcoming Catalysts Timing Drug Milestone Indication 2H16 Otezla Phase II - Top-Line Results Atopic Dermatitis (Eczema) 2H16 Otezla Phase II - Top-Line Results Ulcerative Colitis (UC) 2H16 Revlimid Phase III - CLL-002 Top-Line Results CLL/SLL - NHL 2H16 RPC4046 Phase II HEROES - Trial Completed Esophagitis 2H16 RPC4046 Phase II HEROES - Top-Line Results Esophagitis 2H16 Otezla JNDA Filing Psoriatic Arthritis (PA) 2H16 Otezla JNDA Filing Psoriasis 10/30/2016 Istodax Expiration of 30-Month Stay Cutaneous T-Cell Lymphoma (CTCL) - NHL 11/1/2016 Refludan Patent Expiration Heparin-Induced Thrombocytopenia (HIT) 07/01/2016-12/31/2016 Ozanimod Phase II - Top Line Results Crohn's Disease 07/01/2016-12/31/2016 GI-6207 Phase II - Top-Line Results Thyroid Cancer 12/31/2016 GED 0301 Pediatric Trial Initiation Ulcerative Colitis (UC

  • Bloomberg: Ziopharm CEO Laurence Cooper said his company isn’t affected because it doesn’t use a similar pre-conditioning regimen"

    Juno has asked the FDA for permission to continue the trial without using fludarabine as part of the pre-conditioning treatment. The FDA has told Juno it needs to change its trial protocol, patient consent forms and information it provides to investigators, the company said. Juno plans to submit the information to the FDA this week.

    Competitors Fall

    Shares of competitors testing CAR-T therapies fell in late trading. Kite Pharma Inc. dropped 7.2 percent to $48.33, while Bluebird Bio Inc. slipped 4.7 percent to $46.52 and Ziopharm Oncology Inc. slid 3.8 percent to $5.78.

    “Our program is on track and it is unaffected by today’s news,” David Chang, Kite’s chief medical officer, said in a phone interview. “We believe that we have done all the due diligence a company should do, including for the chemo-conditioning dose.”

    Kite Chief Executive Officer Arie Belldegrun said the company has worked with the National Cancer Institute for 10 years, using that time to fine-tune details and reduce the risk of all aspects of the treatment before starting company-sponsored trials.

    Kite investors shouldn’t be concerned about the Juno news because Kite uses a far lower amount of fludarabine in pre-conditioning patients in trials, according to Eric Schmidt, an analyst at Cowen & Co. who rates Kite shares outperform.

    Kite “has a lot of data to support a low-dose regimen, which is safe and efficacious,” Schmidt said in a phone interview. “Comparing that to a high-dose regimen is apples to oranges.”

    Benefits and Risks
    Pharma giant Novartis uses fludarabine in its studies, said spokeswoman Julie Masow. “We have a positive benefit/risk profile," she said in an e-mail. Ziopharm CEO Laurence Cooper said his company isn’t affected because it doesn’t use a similar pre-conditioning regimen. Bluebird declined to comment.

    Celgene Corp., which last year spent $1 billion to invest in Juno and join it in a 10-year CAR-T partnership, said after the announcement that it stands by the company. In April, Celgene said it would exercise an option to develop and commercialize Juno’s CD19 CAR-T program outside of North America and China. CD19 is a protein on cancer cells targeted by the Juno treatment.

    “Celgene remains committed to Juno’s CD19 franchise and the potentially transformative impact of CAR-T therapy,” Greg Geissman, a Celgene spokesman, said in an e-mail.

    A spokesman for the FDA didn’t immediately comment.

  • Full MTSL ZIOP coms...consistent with my take ..."the new terms with a new management team needed to be in place before the next deal"...ZIOP is a BUY under 12 with a TARGET PRICE of 18

    Full Med Tech Letter – anyone I talk to who has followed Kirk (ZIOP’s Chairman and largest individual shareholder) understands this restructuring sets up the final negotiations for either a HUGE TCR deal plus a side IL-12 deal or an acquisition by Big Pharma/Biotech of ZIOP. I agree with MTSL comments per my previous post on this subject which I will repaste under the MTSL comments. RC

    ZIOP – Enrolls 3 Cohort in GBM & Restructures XON Partnership

    ZIOP has started the enrollment in a third cohort at 30 mgs of Ad-RTS-hIL-12 + orally administered veledimex to treat recurrent or progressive glioblastoma (GBM) or grade III malignant glioma. This follows the successful completion of enrollment in the first (7 patients at 20 mgs) and second dose cohorts (6 patients 40 mgs). To date, toxicities in both dose cohorts were consistent with those previously reported, with a higher incidence of Grade 3 or greater adverse events in the 40 mg dose group. The primary objective of the study is to determine the safety and tolerability of a single intratumoral Ad-RTS-hIL-12 injection activated upon dosing with oral veledimex. The company appears to have found the “sweet spot” for IL-12 expression in the brain with the 30 mg dose. The optimal dosing may be reached sooner than initially anticipated, which would potentially allow for a registration trial to be the next clinical step. The company expects to present updated results from the study at a scientific meeting later in the year.

    ZIOP and their partner XON have restructured their agreement to facilitate increased investment in clinical development by ZIOP. The new terms are:

    Operating profit rates payable to XON from ZIOP on products developed under its two existing collaborations (graft vs. host disease and cancer) will be reduced from 50% to 20%. This reduction will not apply to any royalties or other payments made with respect to the companies’ existing collaboration with Merck KGaA. Economics from any future sublicensing arrangements with potential third party collaborators will remain 50/50.

    In consideration of the amendments, ZIOP will issue shares of a new class of preferred stock that would carry an initial stated value of $120 million and a monthly dividend of 1% payable in additional preferred shares. The shares will convert on the first approval in the U.S. or upon a change of control of ZIOP. The preferred shares issued to XON will be converted into ZIOP common stock equal to the aggregate stated value divided by the volume weighted average closing price of ZIOP’s common stock over the 20 trading days ending on the date that the product approval is announced or a change of control occurs.

    The dosing of the 3 cohort in the IL-12 GBM trial is a positive and could lead to a registration trial that could start as soon as yearend in a patient population that has run out of treatment choices. While the restructured deal appears to favor XON initially, the goal of increasing ZIOP’s R&D investment near term should counter balance the dilution. The restructuring also helps explain why we have not seen any recent partnerships from ZIOP as the new terms with a new management team needed to be in place before the next deal.

    ZIOP is a BUY under 12 with a TARGET PRICE of 18


    Consistent with my previous post:

    re: I believe this deal is a big positive. Investors need to read the tea leaves

    Crystal Clear - Kirk said in Jan their are more international and large pharma/biotechs interested in ZIOP and the immuno-oncology platform then ever before. They have been negotiating a large TCR deal since late last yr. They have a PD-1 partner selected and are in negotiations. Multiple parties have to at least put pencil to paper re aquiring ZIOP. Three things have delayed deals to the frustation of this board.

    1) Kirk will not give this away - needed a little more data and some publications. Has enough now for deals imo.

    2) Feeling Kirk is loose canyon without Pharma experience. Gene G as President answers that in a big way.Need for more pharma experience on Board. Fred Hassan one of the most experienced and respected Big Pharma guys on the planet. Addressed.

    3) the 50% arrangement while incredible for ZIOP to have traded Pali for large % of profits on every immuno-oncology drug XON ever invents now including also MDA SB (especially good for ZIOP with XON paying all the discovery and preclinical expenses) made deals in IL-12 and TCR and possible acquisitions less attractive and much more complicated likely with 3 or 4 or more participants in deals. Yesterdays transaction fixes it all. ZIOP now owns 80% of the profits to every XON immuno-oncology drug for infinity including the entire MDA SB and SB 2.0 and SB 3.0 platforms.

    In my opinion Big Pharma is in late stage negotiations with ZIOP. Adding one of the most respected men in the industry to XON Board Fred Hassan, getting Big Pharma experience in XON as President and this percentage raise for ZIOP to me its all part of current negotitations - Big Pharmas request in order to complete transactions, partnerships or an all out acquisition of ZIOP. Those who follow Kirk understand how he moves chess pieces before he completes the deal. Did it before Scios, New River, Clinical data, MD Anderson deals. Late stages imo. ZIOP is also in better shape than ever to negotiate new partnerships and deals and many of the companies that may have left because of the 50% deal could return to table imo.

  • In my opinion this is a great deal for ZIOP...sets up huge deal...ZIOP now owns (& can sell) the rights to 80% of the profits to every immuno-oncology cancer drug Intrexon ever makes for infinity....

    outside of Merck KGaA deal......this gives , Merck US, BMY, GILD, PFERoche, etc now the ability to buy an unencumbered immuno-oncology platform with 80% potential with XON paying all the preclinical and discovery expenses. A great deal for ZIOP imo. Dilution comments are silly. This is step 1.

    Gilead for instance who IMO Broder was brought back to step up talks, are actively looking for a cancer leader and immuno-oncology platform. They have $4 bill a qtr in cash. Imagine spending less than one quarters cash and getting Cooper to lead your cancer efforts and one of the few immuno-oncology platforms not partnered - especially the key TCR, SB Non-viral, NK OTS and neoantigen advantage in solid tumors all subjects of recent Rosenberg (NCI) platform and now we know NCI is starting to use the rheo switch.

    This deal is a huge win for ZIOP - and for intrexon its a win if they sell the company or do a huge TCR deal with Big Pharma. This is step 1. If you do not see that you do not follow Kirk. Let the Big Pharma bidding begin.

  • ZIOP now owns rights to 80% of profits to every immuno-oncology drug XON ever makes for infinity … Let bidding begin

  • Key Takeaway

    While success in the ph.III Revlimid lymphoma study is not a sure thing, our

    analysis suggests REMARC is more likely than not to work, and regardless we

    see upside/downside as relatively modest ($1/$3 to DCF, though stock move

    could be slightly greater) and see minimal readthrough to other lymphoma

    indications. We would continue to take advantage of recent stock volatility

    on macro/NT catalyst concerns given CELG's strong pipeline and LT growth


    Upcoming data for REMARC expected soon. Recall the ph.III study (n=650) is testing Revlimid maintenance treatment vs. placebo following initial response to R-CHOP in older (60-80 yo) DLBCL pts. Based on CELG's recent comments, we believe the data will be top lined this summer.

    We see several reasons REMARC could be successful. Revlimid has demonstrated clear activity, clinically and preclinically, in suppressing DLBCL. Additionally, we note two recent ph.IIs presented at ASH which support the benefits of Revlimid maintenance in DLBCL, albeit in different populations vs. REMARC.

    Though we believe Revlimid will likely be active, there are some risks to it

    showing statistically significant benefits in REMARC. While Revlimid has been

    tested extensively in lymphomas, it has never been tested directly in REMARC's setting, and variables such as lower relapse rate in front-line pts could reduce ability to show a benefit, especially given a relatively high PFS bar. Inclusion of GCB-type pts, in whom Revlimid may be less active, could also dilute Rev's treatment effect; however, our analysis also suggests the importance of this GCB/non-GCB issue may be overstated, given some evidence Revlimid works in GCB cells, possible Street overestimating the size of GCB pool, and selecting for older pts (which may increase % of pts who would have otherwise relapsed)

    could help offset the effect.

    Overall, we model a 65% prob. of success with modest ($1/$3) upside/

    downside and limited readthrough to other lymphoma indications. Assuming

    ~60% of 1st-line elderly DLBCL pts eligible for maintenance and penetration of 24%, sales could be ~$460M in this indication by 2025. Even if REMARC misses, we believe Revlimid could likely still be active in other settings (e.g., ABC subtype); removing lymphoma completely from our model would reduce DCF valuation by $11.


    Our $140 tgt reflects a DCF analysis. Risk include competition, pipeline failures, and IP.

    We expect upcoming data from REMARC, one of five ph.III trials CELG is conducting in NHL, in the coming weeks. Revlimid is currently approved and used extensively in multiple myeloma, with one approved NHL indication (MCL); while there is a range of data supporting use of the drug in various NHL indications, we believe off-label usage at present is relatively minimal. Based on recent comments at the Jefferies Healthcare Conference, we expect phase III REMARC data to be reported this summer, with data from four other phase III studies in NHL expected over the next 1.5 years.

    REMARC has a unique design that could potentially address a large subgroup of NHL patients, though one limitation in predicting success is that Revlimid has not been specifically tested in this way previously. DLBCL represents the largest subgroup of NHL (~40%) and predominantly affects elderly patients. R-CHOP is potent in induction therapy and can generate a high rate of CRs in frontline DLBCL. However, there is a high rate of relapse in DLBCL; elderly relapse can be ~30-40% and these pts have a very poor prognosis and are challenging to treat into a second relapse. REMARC tests Revlimid maintenance x2 years in elderly patients with DLBCL who respond (CR/PR) to front-line R-CHOP; maintenance data would support registration of the drug for this indication.

  • They got to maximum dose without even one additional death in this very sick population - P/R "All related side effects were reversed upon cessation of veledimex. No subsequent deaths have been reported." of paramount importance imo. Very positive...

    ZIOPHARM Oncology, Inc.

    Jun 27, 2016

    ZIOPHARM Completes Enrollment in Second Patient Cohort and Initiates Enrollment in Third Cohort in Phase 1 Study of Gene Therapy Candidate Ad-RTS-hIL-12 in Brain Cancer

    BOSTON, June 27, 2016 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new cancer immunotherapies, today announced the successful completion of enrollment in the first and second dosing cohorts as well as the initiation of enrollment in a third cohort in the Company's ongoing multi-center Phase 1 study of Ad-RTS-hIL-12 + orally administered veledimex to treat recurrent or progressive glioblastoma (GBM) or grade III malignant glioma. Ad-RTS-hIL-12 + veledimex is a novel viral gene therapy candidate for the controlled expression of interleukin 12 (IL-12), a critical protein for stimulating an anti-cancer immune response.

    The primary objective of the study is to determine the safety and tolerability of a single intratumoral Ad-RTS-hIL-12 injection activated upon dosing with oral veledimex. Secondary objectives are to determine the maximum tolerated dose, the immune responses elicited, and assessment of biologic response. The first cohort of seven patients received 20 mg doses of veledimex, the second cohort of six patients received 40 mg doses of veledimex, and the third cohort will receive 30 mg doses of veledimex to refine the effect of activating the immune response within the tumor. The resultant immunologic activity that follows IL-12 expression in the brain suggests that no further dose escalation will be necessary and the optimal dosing may be reached sooner than initially anticipated.

    Francois Lebel, M.D., Executive Vice President, Research and Development, Chief Medical Officer at ZIOPHARM, commented: "With the RheoSwitch® (RTS®) technology, the only switch currently in the clinic that operates on gene transcription, we have demonstrated the ability for veledimex to cross the human blood brain barrier and activate production of IL-12 in GBM tumors in a dose-dependent manner, giving us the potential to precisely tune the balance between activity and tolerability."

    Data from 11 patients with recurrent high-grade gliomas were recently presented at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting. All of these patients failed at least two prior lines of therapy and underwent partial resection leaving residual tumors, in certain cases with significant tumor burden. Ad-RTS-hIL-12 was administered through direct injection into the brain tumor and veledimex was taken orally to activate the production of IL-12 from the tumor site and stimulate an immune response.

    As of May 18th, the date of data collection for the ASCO presentation, overall median follow up was 6.2 months, with 10 of 11 recipients alive. IL-12 in the bloodstream was measured and was found to be proportional to the amount of veledimex administered, demonstrating that this orally-delivered activator crossed the blood brain barrier to turn on the RheoSwitch® technology in a dose-dependent manner.

    To date, toxicities in both dose cohorts were consistent with those previously reported, with a higher incidence of grade 3 or greater adverse events in the 40 mg dose group. All related side effects were reversed upon cessation of veledimex. No subsequent deaths have been reported.

    The Company expects to present updated results from the study at a scientific meeting later in the year.

    "Overall survival remains the gold standard of therapeutic success in glioblastoma, particularly in high-grade, recurrent disease, where survival is too often measured by just a few months," said Laurence Cooper, M.D., Ph.D., Chief Executive Officer of ZIOPHARM. "We remain encouraged by the outcomes of Ad-RTS-hIL-12 as a single agent tuning the immune system in this GBM study. We believe that these early results also have positive implications for our combination approach utilizing this novel gene therapy with immune check point inhibitors. We look forward to additional follow up as we work to fine-tune dosing levels using the RheoSwitch® technology."

    Ad-RTS-hIL-12 + veledimex has been granted Orphan Drug Designation by the U.S. Food and Drug Administration for the treatment of patients with malignant glioma.

    About Glioblastoma

    Glioblastoma is an aggressive primary brain tumor affecting approximately 74,000 people worldwide each year.i, ii Recurrent glioblastoma is an aggressive cancer with one of the lowest 3-year survival rates, at 3%, among all cancers.iii For patients who have experienced multiple recurrences the prognosis is particularly poor, with a median overall survival (OS) of 6-7 months, while OS in patients that have failed temozolomide and bevacizumab, or equivalent salvage chemotherapy, is approximately 3-5 months.iv, v

  • RBC just out Sunday night-Brexit could end up being a good thing for biotech.....: CELG - continue to like this name, REMARC expectations keep coming down, we think GED-0301 interim futility will be fine.

    Brex-Biotech - Could Brexit end up being a good thing for biotech? How?
    Add'l thoughts on CELG, BIIB, VRTX, BMRN, GILD, AMGN
    June 26, 20
    RBC Capital Markets,

    • With increased global equity market geopolitical concerns and a further -5% pullback in the IBB biotech index on Friday, the IBB is now on key support levels of $249 (it has traded between $249-290 all year and bounced at these levels four times this year). The Friday pullback wasn't that much worse than the S&P500 (-3.6%) and the Nasdaq (-4.1%) and some large cap biotechs like GILD were only down 3-4%. We think global equity uncertainty matters way more than technicals. We're framing the context of where biotech prices are right now and a reminder that sentiment remains tough. Going into this week and summer, an important question we ask is whether bigger picture - could the global "Brexit" concerns end up being a net positive for biotech equities and money flow? How?
    • We could make an argument that Brexit might be positive for biotech stocks and better risk/reward because if economic and political uncertainty continues to weigh on the overall market, then:(1) healthcare and biotech should see less economic uncertainty than other sectors (i.e. higher earnings visibility for healthcare) and a defensive rotation could be in play "shifting money flow" to healthcare and out of more economically sensitive groups until we know more, thus selling riskier sectors and buying less risky earnings sectors, (2) biotech has very low exposure to UK (1% of revs on average) and not that much to the Euro (20% of revs on average, i.e. half of their OUS revenues which are about 20-40% on average) and they also hedge currency; see exposures on page 2 from our note on Friday (AMGN and BIIB have the least OUS exposure)

  • ISI - ***BREXIT - exposure to the UK is small for our companies

    Given the Brexit vote, we've received questions today on our companies' exposure to the UK. We've asked our companies. Below is what we learned (this is a work in a progress, we’ll follow up as we get more):

    ABBV: ~3% of revenues

    BMY: less than 5% of revenues

    MRK: well under 5% of revenues

    PFE: ~2% of projected 2016 revenues

    LLY: exposure is minimal because not a top 5 market (EU as a whole is ~20% of revenues)

    ZTS: ~3.5% of revenues

    AMGN: waiting to hear back

    BIIB: waiting to hear back

    CELG: less than 1% of revenues

    GILD: ~2.9% of revenues*

    REGN: waiting to hear back

    BMRN: waiting to hear back

    VRTX: roughly ~2.5% of revenues**

  • First and for the fifth time - those who continue to bring up melanoma either have not talked to old or new management or are purposely trying to mislead. The melanoma trial - if you talked to the ex CEO - was never designed to proceed to Ph 3 nor did they ever contemplate approval in this area. It was designed as the easiest solid tumor to treat with IL-12+V and to 1) see if the Rheo Switch worked in Humans and 2) see if they could get systemic activity of the IL-12 and 3) show that the difficult IL-12 SAE's and Grade 3 toxicity that halted other IL-12 trials (powerful drug difficult side effects without the switch) could be handled.

    The company considered the melanoma safety trial a success in that indeed proved the Rheo Switch worked in humans, showed efficacy and importantly showed a systemic response. It helped them design the Glioma trial and served its purpose. It was never contemplated as a trial to start a march to commercialization. Those positioning the melanoma trial as a failure and continuing to ask the status of it - well they have not talked to either the previous or current CEO about it - that is clear.

    If you bother to talk to Cooper or I/R - they will tell you Merck is still testing the targets in preclinical, are excited about the partnership, are working closer with Cooper than ever before (head of Merck KGaA immuno-oncology ex Cooper colleague who Cooper ate lunch with often who is a big supporter of Cooper unlike his predecessor is not in Germany but in MA 20 miles from ZIOP and Cooper and they are expanding their R&D building). Kirk has told people Merck is excited and happy about the partnership. Merck told everyone from the start they will not announce the targets until the Ph 1 starts for competitive reasons. We know from Kirk's comments they are not "me-too CD-19 targets".

    Breast data since January the company has guided not to expect evaluable Breast Data until late in the yr - probably at the December San Antonio Breast conference or maybe SNO. I think one of the missteps was having abstracts on Breast in Q4 and Q2 at ASCO - which for those not following the company closely - built up a false expectation that there would be evaluable data. Never was the expectation for those who followed the company comments.

    Merck KGaA situation is a little slower than we hoped - that happens and if you look at what is most exciting in the three publications this yr - 2 from Rosenberg (one co-authored by Cooper) - you see the bind Merck KGaA is in with their limited scope CAR T deal. Merck taking longer in preclinical which in retrospect makes sense since they are trying something besides the standard CD-19 target - so you want some preclinical work to design the Ph 1 right - also since Merck's deal requires large payments that could total $3.8 billion if they take 8 targets but is limited to the less powerful CAR T without TCR, neoantigen advantage in solid tumors, off the shelf NK Cells (the things Rosenberg and others published on this yr and are raving about) - it is likely Merck would like to include some of these things in their trials - which is out of scope of original CAR T contract and would require some negotiation.

    Cooper is working more and more with NCI's Rosenberg so it appears a large TCR or other deal would have to include four parties with a myriad of IP issues - talked to a wall st veteran the other day and he was involved in a deal where one IP page in a deal document took months to get approved before deal went forward - imagine how complicated something would be if you had XON-ZIOP-NCI-Big Pharma.. Also in a month or so IL-12 Cohort 1 could have survival that leads to FDA discussions about registrational trial. And we know from KOL dinner that ZIOP has selected PD-1 partner likely not Merck KGaA (more PDL-1) and if they are starting this yr as disclosed recently then negotiations have to be on going. This alone would preclude open market purchases by those involved in the discussions. To me there are likely TCR, PD-1 and IL-12 separate negotiations going on. Kirk won't give anything away and the TCR deal would be particularly complicated. So no prediction if or when something gets done. But signs are they cannot and have not been able to buy. We should hear about who will provide the PD-1 for the combo trial - appears first will be an approved product and imo it is looking more and more like Merck US maybe Keytruda. I also think they will do a combo with non-approved PD-1s... the preclinical efficacy boost when PD-1 was added to IL-12 + V was exactly as Cooper predicted last June when he designed trial. Now we need to get the human trial started.

    So I advise stop looking back at melanoma and start looking to the publications ( I post some things about them after this post) and the things more powerful than CAR T or areas like Off the Shelf NK science that Cooper has said to me on a phone call he thinks can make CAR trials more powerful (again that would be outside the scope of Merck CAR deal and require renegotiation). Its the TCR area where ZIOP-MDA-XON can more rapidly develop clinical grade TCR T-cells faster and cheaper than the competition. Or per the Rosenberg publication - the fact of MUCH cheaper non-viral TCR and some think much safer - where the Rosenberg publication cites ours as 1/10th the cost of the competition. And the OTS NK cell trial from MDA OTS (even though XON has the rights to Patrick S's NK companies NK cells - Cooper thinks MDA's are more suited). Or if you talk to Cooper - one of the things he is most excited is the neoantigen advantage he strongly believes will be the "keys to the kingdom" in the much more difficult and much more lucrative solid tumor area.....People can joke about that comment - I find the ones who do joke about it are the ones who have not met Cooper and looked in his eyes and see his true excitement when he says it. And the excitement is not about money - or stock price - he really believes it is the key to treating solid tumors.

    So I agree lets talk fundamentals - I will repost some of the comments and slides of this yrs publications - problem is those most critical who want to talk fundamentals - they never opine or reply to the fundamental posts or the publications. They bring up melanoma instead as a red herring. Lets move forward. And as far as deals - they still are in discussions. As polo-grill says often deals take yrs - Kirk has a history of delivering deals well after many hoped - but then coming through - almost all well after when they were originally hoped for. The sector massacre likely delayed the ability to get what he wanted....but you can be sure he is still in heavy negotiation. He will come through. And for those who think you need massive data to do a deal - well the MD Anderson deal and the huge Merck KGaA CAR T deal proves that wrong. IMO the publications and early TCR and NK OTS and neoantigen advantage with Cooper discussing have people interested. When will Kirk get what he thinks for a TCR partnership or an IL-12 deal? Who knows. But don't count he or Cooper out yet. ZIOP is in its current form since Kirk said he would "fix ZIOP" when it was at $2 about 19 months. Cooper has been CEO about a yr - a yr in which the sector has been absolutely devastated but Cooper is quietly made an awful lot of progress - slower than many would like - but fundamentally ZIOP is in much better shape now than it was last July at its highs. The ability to stop taking an oral ligand to rapidly reverse the Serious Adverse IL-12 events and Grade 3 toxicity and then days later being able to restart the gene therapy by simply starting the oral ligand is more important than people think. Charles Peacock skiing a yr after the ZIOP IL-12 therapy started should remind us all what this is about. Adding a Big Pharma superstar like Geno G as XON President is also an incremental positive not being fully grasped by Wall St. I am convinced this time next yr there will be a much more positive tone on this board. Give Cooper 2 yrs instead of one - give Kirk a little more time for negotiations given the sector situation. There is enough Big Pharma companies in desperate need of immuno-oncology and a lack of unpartnered programs. Kirk and Cooper and Geno G will come through.

  • rob_cos rob_cos Jun 5, 2016 4:59 PM Flag

    Remember Cooper said their neoantigen advantage in TCR (more powerful than CAR T) will be the keys to the kingdom in solid tumors. First approved will be IL-12 in GBM with the amazing rheo switch

  • rob_cos rob_cos Jun 5, 2016 4:56 PM Flag

    Important post from IV - this is key - patients will have overall survival advantage in another month or so. They will get registrational go ahead by FDA and from the MTSL and Griffin note - it appears Merck wants this -which makes sense as their lead PD-1 would get a nice efficacy boost and assure approval. There is a reason they hired a big Cooper fan former colleague who he ate lunch with daily and moved him not to Germany but 20 miles away from ZIOP HQ in MA and are adding to the building and adding R&D 20 miles from ZIOP

  • Differnetiator: No company has ever been able to RAPIDLY REVERSE IL-12 SAE's & Grade 3 Toxicities by simply discontinuing the daily oral ligand.....& then days later be able to RESTART THE GENE THERAPY by resuming daily pill.

    No company has ever been able to RAPIDLY REVERSE IL-12 SAE's and Grade 3 Toxicities by simply discontinuing the daily oral ligand.....and then days later be able to restart the gene therapy by resuming the daily pill. No one. It certainly is a differentiator over simple expression or a suicide switch where you have to kill the gene therapy completely (therapy is shut down forever/discontinued) and a certain differentiator from something like the Duke polio trial where once in the polio is not controlled at all.

  • Adam F is out of bullets-talking about the old pre-Cooper trials more than the fabulous new data, no mention of MDA, Merck, NCI or Rosenberg publications...silly
    First a reminder Adam has been negative on ZIOP since $2 and missed the run to $14s before the sector knockdown. And although the sector massacre has devastated biotech since the Hillary tweet, ZIOP is outperforming the XBI again this yr and was up 64% last yr vs an XBI that was up 13%. He attacks RJ Kirk related equities and is almost always wrong...Who can forget this article on Kirk's Clinical Data (CLDA) when the stock was about $17…went down to $14's in month…When this article came out CLDA was about $17 a share. This article helped cast doubt and said CLDA's drug would likely not be approved (it was approved shortly thereafter) and like XON stock after the SA piece fell for weeks - bottoming near $14….Again about 2 months after this article CLDA was acquired by Forrest Labs for $30 and a CVR that had a possible max payout of $6….the stock DOUBLED from the Adam F article date ($17) to $34

    NOTICE ADAM ALSO THIS TIME DOES NOT ALLOW COMMENTS TO BE POSTED UNDER TODAY'S ZIOP STREET.COM ARTICLE...Last week I tried to publish comments to counter his negative mailbag comments but he selects what not to publish. Today he is allowing NO comments under his purposely misleading article that leaves all of the below out.

    Its Deja Vu all over again. Like the CLDA article, this article is silly - the former ZIOP CEO Lewis (Not current MD Anderson superstar immuno-oncology expert Dr Cooper) started the two old trials and never intended to go after approval in was designed to see if Veledimex could control the IL-12 and to see if it had a systemic response. Learnings from those two trials were taken to design this so far very successful glioma trial - his biggest complaint seems to be we did not get all the data in the abstract. Guess what - that is how ASCO works - you have to save detail for the actual presentation...of course he does not tell readers that ZIOP gave investors more than 80% of the companies with abstracts by giving updated data in a press release. So ZIOP gave way more of an update and detail than most. Also his continued harping on ORR and tumor shrinkage shows he has done little due diligence. It appears all of the first cohort have had their tumor removed. Adam in his tweets and article harps on no ORR - but ignores the patients are living longer than the expected median survival in a Ph 1 trial designed to give safety and max dose information not efficacy but yet at the lower dose patients are living longer than the estimated median survival and the data is still maturing. Also Adam acts like holding back some detail for the actual ASCO presentation is unusual. Truth is ASCO expects it and ZIOP actually UPDATED the older abstract data with months more of updated data and detail. In reality, ZIOP gave more additional updated data since the abstract in their PR than probably 95% of the other companies with ASCO abstracts. ZIOP disclosed way more data and updated data than most companies. They should be lauded not criticized for keeping some detail (as encouraged by ASCO) for the actual presentation in a few weeks.
    Adam postulates that most of ZIOP's market cap is because of RJ Kirk. Partially right. ZIOP traded an old drug for the rights and 50% of the profits of every XON human cancer drug XON invents. And XON allows ZIOP a very slow cash burn because it pays for all of ZIOP's preclinical and drug discovery expenses, all of the rheo switch and hundred other switches in development, all of the salaries and benefits of over 100 discovery PhD's employed at XON as well as all of the salary and benefits of Dr Broder, Dr Reed and RJ Kirk himself. But of course ZIOP is actually undervalued not overvalued and Adam makes no mention of the brilliant CAR T deal for up to 8 targets with Merck KGaA a $35 billion pharma company - which if milestones are hit on 8 targets could bring in $3.8 billion dollars. Also underestimates the deal with MD Anderson the largest cancer clinic in the world and the National Cancer Institute and gene immuno-oncology expert Dr Steven Rosenberg and his recent publications praising the ZIOP-MDA science which is cheaper and safer than competitors. Also missing in the constant talk about competitor CAR T chronologic lead is the discussion of the more powerful areas Dr Cooper and ZIOP and MD Anderson are excelling in such as TCR with development of clinical grade T cells (faster and cheaper than competition), NK cells Off the shelf trial about to start with NK cells OTS from MDA, the neoantigen advantage ZIOP has in solid tumors, etc....Some of this is addressed in the three scientific publications Adam does not address at all in his hit piece.

    Yes this article grossly underestimates the quality of Intrexon's preclinical drug discovery and switch work and the science going on with MD Anderson/ZIOP/XON/NCI

    1) Partner MD Anderson is the LARGEST CANCER CLINIC IN THE WORLD.

    Partner National Cancer Institute is the most important US cancer agency and partner Dr Rosenberg at NCI is one of the most respected gene therapy experts in the world – the recent star of the PBS cancer Series.Just two days after announcing the Merck KGaA deal, Intrexon signed a CRADA (Cooperative Research and Development Agreement) with the prestigious National Cancer Institute to investigate RheoSwitch® controlled IL-12 cancer therapies using T-cell receptors (TCR) derived from peripheral blood. The lead investigator on this collaboration will be none other than the legendary Dr. Steven Rosenberg - the gene therapy superstar who was prominently featured on the highly acclaimed PBS Ken Burns series - Cancer - the emperor or all maladies.

    Already this yr alone Dr Rosenberg of NCI has authored TWO articles related to XON/ZIOP/MD Anderson gene therapy science:
    A March 5 2016 article Dr Rosenberg co-authored with ZIOP CEO Dr Cooper in Molecular Theory March 5 scientific publication per slide 15 of Jeffries Cooper Presentation - "Stable, Nonviral Expression of Mutated Tumor Neoantigen-specific T-cell Receptors Using the Sleeping Beauty Transposon/Transposase System"


    Earlier this yr Dr Rosenberg was an author in the important article TCR: Targeting private somatic mutations (neoantigen)-Nature Medicine (Dr Steven Rosenberg) - Prospects for gene-engineered T cell immunotherapy for solid cancers-Non-viral great promise - ONE TENTH the cost of therapies from JUNO or KITE....while competitors play in the me-too CD-19 space Cooper and Rosenberg are leapfrogging them in TCR, neoantigen targeting of solid tumors and off the shelf NK cells....

    Off the Shelf NK cell trial this yr in AML & brain cancer early next...Target tumors with loss of HLA, killing is independent of specific known target antigen, Cytokines are "fuel" for NK cells

    Meanwhile - adding ZIOP/XON IL-12 + veledimex to PD-1's (like Opdivo or Keytruda) have enhanced poor efficacy in glioma and resulted in 100% survival in preclinical tests recently disclosed (with human IL-12+veledimex data coming weds ASCO in glioma)

    IL-12+V enhancing checkpoint (PD-1s like Opdivo) efficacy VERY important-complimentary to human data at ASCO perfectly fits Cooper June 2015 prediction & ties into Cooper's theory as to why Opdivo/Keytruda need IL-12+V - now add the + Cooper comments in the press release

    Of course patient #1 in ZIOP Glioma trial blogs and his tumor is not growing back 11 months on drug (vs median survival expected 3 to 5 months) after failing other therapies


    And of course the amazing results to date with 10 of 11 patients surviving past the estimated median survival expected on the lowest dose in a safety and max dose trial.

    Yes this article grossly underestimates the quality of Intrexon's preclinical and drug discovery work which feeds ZIOP clinical trials and the expense reduction the agreement causes in the key early yrs and the science going on with MD Anderson/NCI/ZIOP/XON/Merck

    Adam is out of bullets - had to go back to the pre-Cooper trials, not mention the Rosenberg publications or the partners above and the potential economics and try to confuse talking about ORR and tumor shrinkage when the first cohort has resection. Like last weeks XON attack expect this silly article to have little more than a brief half a day effect. We know the true story.

  • Forbes-Duke trial - 8 of 19 have died - 3 have achieved LT remission. They cannot control the polio. ZIOP has the first ever controlled IL-12 treatment & permeates BBB...
    Was traveling so I finally just watched the 60 minutes piece (which was an update of an earlier segment I had seen with much of it from the first showing) - I'm told by one poster here we are down this week because of 60 minutes piece - if so that is actually a relief - they have no control of the polio virus - hope it works but I think the first ever controlled IL-12 treatment will be more promising for control and safety. Also lets see our survival tomorrow - 8 of 19 have died in their trial. This is promising but certainly no reason to sell ZIOP. Remember the disclosure on the 60 minutes piece the doctors are investors in the company that will bring this to market. Have to keep that in mind. Lets see our data tomorrow.

    May 16, 2016 @ 03:04 PM 29,135 views
    What '60 Minutes' Still Isn't Saying About The 'Miracle' Glioblastoma Drug
    Arlene Weintraub ,
    I cover the science and business behind drug development and health
    Opinions expressed by Forbes Contributors are their own
    Last night, the hit CBS CBS -0.35% news program 60 Minutes revisited a trial at Duke University that it had devoted two segments to early last year. Scientists at Duke are testing a modified form of the polio virus to treat glioblastoma, and the reason for the 60 Minutes update was that the research has recently been granted “breakthrough” status by the FDA—which may shave some time off the development pathway. The development of engineered viruses, or “oncolytic viruses,” to treat cancer is one type of immunotherapy that’s generating excitement in oncology circles.
    The breakthrough status for Duke is good news, to be sure. Median survival for patients with glioblastoma who are treated with traditional chemotherapy is only about 14 months and two-year survival is 30%, according to the American Brain Tumor Association. The disease claims 12,000 people per year in the U.S. and was to blame for the death of Vice President Joe Biden’s son. Biden is now leading the government’s cancer “moonshot” initiative, and as part of that he visited Duke, where he met the first patient treated with the virus, Stephanie Lipscomb, who entered the trial in 2012 and is still cancer-free.
    But winning breakthrough status from the FDA doesn’t guarantee that any treatment is actually a breakthrough. The Duke team has plenty of hurdles to overcome before the modified virus can become an approved treatment. In fact, the 60 Minutes segment revealed that one of the patients hailed as a miracle in last year’s broadcast, Nancy Justice, suffered a recurrence of her brain tumor and died on April 6 at age 60.
    And it’s important to remember that Justice, Lipscomb and the other 19 patients treated so far were in a Phase I trial in which eight patients have died, three have achieved long-term remissions and the rest are still being monitored. That means it’s too early to judge how the virus will perform in a larger patient population.
    Here are some other key points to keep in mind about Duke’s cancer-fighting polio virus.
    Polio is not the only virus that’s been shown to work against cancer. Several companies and academic groups are testing a variety of engineered viruses to fight cancer, including herpes, vaccinia (cowpox) and adenovirus. And in October, the first virus-based drug was approved by the FDA, Amgen AMGN -2.06%’s Imlygic (talimogene laherparepvec, or T-VEC) for the treatment of melanoma. It’s an engineered form of the herpes virus that’s injected straight into melanoma tumors, where it kills cancer cells directly and also recruits immune-boosting cells to the tumors to boost its potency. It’s far from a miracle—studies show that it works best in a small subset of patients who are in Stage III of the disease, but overall it improves survival by only a few months—which is likely why the FDA declined to fast-track the drug to market last year.

  • ZIOP – Shows Rather Impressive Preclinical Data at ASGCT, Up Next Human Data at ASCO

    ZIOP was front and center at the 2016 Meeting of the American Society of Gene and Cell Therapy (ASGCT) in Washington D.C. last week. The company presented exciting preclinical data for IL-12 in combo with a PD-1 that showed 100% survival. The non-viral Sleeping Beauty (SB) system was also on display. In our view, this technology should be particularly important in leveraging T-cell receptors (TCRs) to target neoantigens in solid tumors which requires individualizing this immunotherapy, an approach that is possible with a customizable, easy-to-manufacture non-viral gene transfer system. ZIOP is poised for a clinical explosion as they expect to initiate or continue prosecuting up to six clinical trials across multiple platforms in 2016, and potentially a registration trial for IL-12 in malignant glioma patients in 2017.

    Preclinical studies combining Ad-RTS-IL-12 + veledimex and checkpoint inhibitors in brain tumor models presented at ASGCT

    In an oral presentation, ZIOP presented data from preclinical studies of Ad-RTS-IL-12 + veledimex combined with immune checkpoint inhibitors (iCPI) in GBM mouse models at ASGCT. Results demonstrated that survival of mice treated with Ad-RTS-IL-12 + veledimex and anti-PD-1 therapy was superior to either treatment alone, with a combination showing 100% survival. Because Ad-RTS-IL-12 and anti-PD-1 are clinically available, these data provide impetus for evaluating this combination immunotherapy in humans. ZIOPHARM plans to initiate a combination study in 2016 and is currently in discussions with partners to provide anti-PD-1 therapy. Given the hyper competitiveness of the PD-1 space, we expect a deal to be announced sooner than later. It is important to remember that PD-1s as a monotherapy only work in about one third of the potential patients leaving a huge opportunity for drugs that can address the other two thirds with combination therapy.

    Preclinical study showing evolution of the Sleeping Beauty (SB) non-viral transposon-transposase system in a mouse model of leukemia presented at ASGCT.

    In an oral presentation, MD Anderson researchers in collaboration with ZIOPHARM presented data from preclinical studies demonstrating the ability to address the challenges of streamlining the manufacture of cell based therapy by leveraging the non-viral SB system to reduce cell culture time. These data also demonstrated an improvement in the anti-tumor activity of the CD19-specific CAR by modifying the “stalk” of the CAR.

    Encouraging data from Phase I brain tumor study to be presented at ASCO.

    ZIOPHARM expects to present data from a multicenter, Phase I gene therapy study of Ad-RTS-IL-12 in patients with recurrent or progressive GBM or Grade III malignant glioma at the 2016 ASCO Annual Meeting in June (, June 2-7, Chicago).

    Following reporting of encouraging data from the first cohort of the study at the initial dosing of Ad-RTS-IL-12 + veledimex, the Company announced last March that the first patient had been enrolled in the study’s second dose cohort – implying acceptable safety at the very least, if not responses as well. ZIOP has publicly said recently that they are encouraged by the survival results observed to date. In our view, this data has the potential to be a significant catalyst for the stock as these patients are very sick with no treatment choices and a life expectancy of as little as 10 weeks. Survival data in particular is the gold standard in cancer drug development and any positive survival signal will catch the attention of biotech investors, as this drug candidate could be in registration trials as soon as next year.

    ZIOP is a BUY under 12 with a TARGET PRICE of 18

  • Over 1000 Oct 10 calls bought today.

  • Today right at close we should get AGSCT presentation showing adding IL-12+Veledimex to Opdivo, etc enhances efficacy in glioma to 100% survival...
    we know from Cooper and I/R its the APPROVED PD-1 drugs they tested but the abstract didn't name the drugs - while we know Kirk/Cooper are already in discussions with the PD-1 companies per the P/R - I would love it if the presentation included the names of the PD-1s.....would be a big bonus...see presentation 4 pm start per MTSL below...

    Bioinvest Medical Tech Stock Letter...ZIOP – Poised to Shine at ASGCT With Oral Presentations & ASCO Next-cheaper CARs with SB to leap frog KITE/JUNO 1st gen...IL-12 PD-1 combo/SB cheaper CARs not in current valuationBuy

  • rob_cos rob_cos May 1, 2016 8:21 PM Flag

    Yahoo not letting me post the entire note or the XON note - see Investorvillage ZIOP board for both must read notes

  • Bioivest Medical Tech Stock Letter...ZIOP – Poised to Shine at ASGCT With Oral Presentations & ASCO Next-cheaper CARs with SB to leap frog KITE/JUNO 1st gen...IL-12 PD-1 combo/SB cheaper CARs not in current valuationBuy

174.80-0.82(-0.47%)Sep 23 4:00 PMEDT